Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2017-01-23 Director's Dealing
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 150.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details changes in securities holdings and contracts related to a company director, including dates, number of shares held before and after the change, and nature of transactions. This matches the definition of a Director's Dealing report, which reports personal share transactions by company directors and executives (insider trades). The document is not an announcement of a report, nor a full financial report, but a specific notification of director share transactions.
2017-01-23 English
Change of Director's Interest Notice 2 pages 134.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares disposed and the nature of the transaction (off-market trade). The document is a formal notification of a director's personal share transactions, which aligns with the definition of 'Director's Dealing' filings. The document length is 3153 characters, which is consistent with a notice rather than a full report. Therefore, the appropriate classification is 'DIRS' for Director's Dealing.
2017-01-23 English
Change in substantial holding 2 pages 1.5MB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001. It details changes in voting power and relevant interests of a substantial shareholder in a company, including dates, share classes, and associations. This type of filing is a notification of changes in significant share ownership levels, which matches the definition of Major Shareholding Notification (MRQ). The document is not an annual report, earnings release, or any other financial report but a regulatory disclosure about shareholding changes.
2017-01-23 English
Investor Presentation 62 pages 5.3MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about Phylogica Limited's proprietary peptide therapeutics technology, including company overview, technology platform, scientific data, and potential applications. It contains multiple slides with scientific figures, data tables, and descriptions of the technology and its advantages. The content is structured as a presentation with sections like 'Company and Technology Overview', 'FPP Delivery Platform', and 'Oncology Programs'. There is no indication that this is a regulatory filing, financial report, or announcement. The presence of disclaimers and forward-looking statements is typical for investor presentations. The document length (15,000 characters) and detailed scientific content further support that this is a presentation rather than a brief announcement or regulatory filing. Therefore, the document best fits the category of an Investor Presentation (IP).
2017-01-10 English
Change in substantial holding 2 pages 240.7KB
Regulatory Filings
2016-12-21 English
Operational Update 4 pages 296.8KB
Management Reports Classification · 95% confidence The document is titled 'Operational Update' and dated 21 December 2016. It provides a detailed progress report on the company's intracellular delivery technology, oncology program, and collaborations over the last quarter. It includes substantive information on technology development, preclinical progress, collaborations, milestone payments, and future outlook. There are no indications that this is a full annual or interim financial report, nor is it a transcript, audit, or regulatory filing. The content is a comprehensive update on operational progress and business development activities, typical of an operational or management update report. Given the detailed nature and length (over 10,000 characters), it is not a brief announcement or a simple report publication notice. The best fitting category is Management Reports (MDA), which covers management's detailed explanation of business trends and outlook, consistent with the document's content.
2016-12-20 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.